Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine IMA203-101)
TCR-engineered T Cells in Solid Tumors (ACTengine)
Sponsor: Immatics
Enrolling: Male and Female Patients
IRB Number: AAAS6579
U.S. Govt. ID: NCT03686124
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The goal of the study is to learn if it is safe to give genetically changed T cells in combination with standard-of-care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of the study drug and if the study drug can help to control the disease. Cancers include bladder cancer, breast cancer, colon and rectal cancer, gynecologic cancers, liver cancer, lung cancer, skin cancer, pancreatic cancer, prostate cancer, stomach cancer, and thyroid cancer.
This study is closed
Ran Reshef, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have recurrent or refractory solid tumor cancer? Yes No
Are you willing to undergo testing, such as biopsies and blood draws? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator